ChromaDex Corporation – NASDAQ:CDXC
Founder-led company
ChromaDex stock price today
$7.886
+2.36
+42.86%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market open
Closed in about 1 hour
ChromaDex stock price monthly change
+111.49%
month
ChromaDex stock price quarterly change
+111.49%
quarter
ChromaDex stock price yearly change
+280.69%
year
ChromaDex key metrics
Market Cap | 415.37M |
Enterprise value | 83.52M |
P/E | -6.22 |
EV/Sales | 1.15 |
EV/EBITDA | -5.38 |
Price/Sales | 1.38 |
Price/Book | 3.47 |
PEG ratio | -0.15 |
EPS | -0.04 |
Revenue | 83.16M |
EBITDA | -1.60M |
Income | -3.52M |
Revenue Q/Q | -1.78% |
Revenue Y/Y | 7.52% |
Profit margin | -22.96% |
Oper. margin | -25.85% |
Gross margin | 59.4% |
EBIT margin | -25.85% |
EBITDA margin | -1.93% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeChromaDex stock price history
ChromaDex stock forecast
ChromaDex financial statements
| Jun 2023 | 20.32M | -2.19M | -10.78% |
|---|---|---|---|
| Sep 2023 | 19.49M | -959K | -4.92% |
| Dec 2023 | 21.19M | 114K | 0.54% |
| Mar 2024 | 22.15M | -492K | -2.22% |
| Mar 2024 | 22.15M | -492K | -2.22% |
|---|---|---|---|
| Sep 2025 | 28.8M | 1.12M | 3.91% |
| Oct 2025 | 29.3M | 1.50M | 5.14% |
| Dec 2025 | 31.03M | 2.25M | 7.27% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 53171000 | 26.02M | 48.94% |
|---|---|---|---|
| Sep 2023 | 53483000 | 26.17M | 48.94% |
| Dec 2023 | 54964000 | 26.50M | 48.23% |
| Mar 2024 | 54079000 | 25.12M | 46.47% |
| Jun 2023 | 3.28M | -5K | -10K |
|---|---|---|---|
| Sep 2023 | 396K | -26K | -3K |
| Dec 2023 | 574K | -21K | -1K |
| Mar 2024 | 284K | -41K | -3K |
ChromaDex alternative data
| Aug 2023 | 113 |
|---|---|
| Sep 2023 | 113 |
| Oct 2023 | 113 |
| Nov 2023 | 113 |
| Dec 2023 | 113 |
| Jan 2024 | 113 |
| Feb 2024 | 113 |
| Mar 2024 | 106 |
| Apr 2024 | 106 |
| May 2024 | 106 |
| Jun 2024 | 106 |
| Jul 2024 | 106 |
ChromaDex other data
30.15%
+0.54%
of CDXC is owned by hedge funds
20.25M
+49.92K
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Aug 2024 | 11408715 | 11431715 |
| Nov 2024 | 2907 | 0 |
| Dec 2024 | 0 | 37161 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Option | JAKSCH FRANK L JR director | Common Stock | 50,001 | $3.66 | $183,004 | ||
Sale | JAKSCH FRANK L JR director | Common Stock | 37,161 | $6.19 | $229,952 | ||
Option | JAKSCH FRANK L JR director | Employee Stock Options (right to buy) | 50,001 | $3.66 | $183,004 | ||
Purchase | PAMIR OZAN officer: Chief Financial Officer | Common Stock | 2,907 | $7.36 | $21,396 | ||
Option | PATRICK KRISTIN director | Common Stock | 20,000 | $1.67 | $33,400 | ||
Option | PATRICK KRISTIN director | Stock Option (right to buy) | 3,000 | $1.64 | $4,920 | ||
Option | PATRICK KRISTIN director | Common Stock | 3,000 | $1.64 | $4,920 | ||
Sale | PATRICK KRISTIN director | Common Stock | 23,000 | $3.57 | $82,110 | ||
Option | PATRICK KRISTIN director | Stock Option (right to buy) | 20,000 | $1.67 | $33,400 | ||
Sale | LI KA SHING 10 percent owner | Common Stock | 11,408,715 | $32,058,489.15 | $365,746,166,042,942 |
| Quarter | Transcript |
|---|---|
| Q1 2024 8 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 6 Mar 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 8 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 9 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Mr. Robert N. Fried (1960) Chief Executive Officer & Director | $810,270 |
| Mr. Frank Louis Jaksch Jr. (1968) Co-Founder & Executive Chairman | $592,420 |
Mr. Kevin M. Farr CPA (1958) Chief Financial Officer | $479,600 |
-
What's the price of ChromaDex stock today?
One share of ChromaDex stock can currently be purchased for approximately $7.89.
-
When is ChromaDex's next earnings date?
Unfortunately, ChromaDex's (CDXC) next earnings date is currently unknown.
-
Does ChromaDex pay dividends?
No, ChromaDex does not pay dividends.
-
How much money does ChromaDex make?
ChromaDex has a market capitalization of 415.37M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 15.99% to 83.57M US dollars.
-
What is ChromaDex's stock symbol?
ChromaDex Corporation is traded on the NASDAQ under the ticker symbol "CDXC".
-
What is ChromaDex's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of ChromaDex?
Shares of ChromaDex can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are ChromaDex's key executives?
ChromaDex's management team includes the following people:
- Mr. Robert N. Fried Chief Executive Officer & Director(age: 65, pay: $810,270)
- Mr. Frank Louis Jaksch Jr. Co-Founder & Executive Chairman(age: 57, pay: $592,420)
- Mr. Kevin M. Farr CPA Chief Financial Officer(age: 67, pay: $479,600)
-
Is ChromaDex founder-led company?
Yes, ChromaDex is a company led by its founder Mr. Frank Louis Jaksch Jr..
-
How many employees does ChromaDex have?
As Jul 2024, ChromaDex employs 106 workers.
-
When ChromaDex went public?
ChromaDex Corporation is publicly traded company for more then 17 years since IPO on 25 Jun 2008.
-
What is ChromaDex's official website?
The official website for ChromaDex is chromadex.com.
-
Where are ChromaDex's headquarters?
ChromaDex is headquartered at 10900 Wilshire Boulevard, Los Angeles, CA.
-
How can i contact ChromaDex?
ChromaDex's mailing address is 10900 Wilshire Boulevard, Los Angeles, CA and company can be reached via phone at +31 3886706.
ChromaDex company profile:
ChromaDex Corporation
chromadex.comExchange:
NASDAQ
Full time employees:
106
Industry:
Biotechnology
Sector:
Healthcare
ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers, as well as to distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and IMMULINA, a Braun-type lipoproteins, including spirulina extracts and active compounds, which are used to support human immune function. It also offers analytical reference standards and services comprising supply of products to conduct quality control of raw materials and consumer products in dietary supplements, cosmetics, food and beverages, life sciences, and pharmaceutical industries. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation is headquartered in Los Angeles, California.
10900 Wilshire Boulevard
Los Angeles, CA 90024
Los Angeles, CA 90024
CIK: 0001386570
ISIN: US1710774076
CUSIP: 171077407
